TABLE 2.
Microbiological characteristics of 190 patients with MRSA bacteremia according to treatment group and outcome
| Variable | All (n = 190) | Treatment group |
Treatment outcome |
||||
|---|---|---|---|---|---|---|---|
| Vancomycin (n = 134) | Teicoplanin (n = 56) | P | Success (n = 112, 58.9%) | Failure (n = 78, 41.1%) | P | ||
| MIC, μg/ml [median (IQR)] | |||||||
| Vancomycin | 1.5 (1.0–1.5) | 1.5 (1.0–1.5) | 1.0 (1.0–1.5) | <0.001 | 1.5 (1.0–1.5) | 1.5 (1.0–1.5) | 0.324 |
| Teicoplanin | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) | 3.0 (2.0–3.0) | 0.039 | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) | 0.476 |
| No. (%) with vancomycin MIC of ≥1.5 μg/ml | 106 (55.8) | 87 (64.9) | 19 (33.9) | 0.001 | 67 (59.8) | 39 (50.0) | 0.180 |
| No. (%) with teicoplanin MIC of MIC ≥ 4 μg/ml | 64 (33.7) | 53 (39.6) | 11 (19.6) | 0.008 | 42 (37.5) | 22 (28.2) | 0.182 |
| No. (%) with CA-MRSAa phenotype (18, 19) | 31 (16.3) | 25 (18.7) | 6 (10.7) | 0.101 | 21 (18.8) | 10 (12.8) | 0.199 |
a
CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus.